Table of Contents: Oncotarget’s Volume 12, Issue #15

Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 15.

Oncotarget's Table of Contents

ONCOTARGET’S VOLUME 12, ISSUE #15

NEW PUBLICATIONS

Listen to an audio version of this post
COVER (PRIORITY RESEARCH PAPER): TERPYRIDINE PLATINUM COMPOUNDS INDUCE TELOMERE DYSFUNCTION AND CHROMOSOME INSTABILITY IN CANCER CELLS

Origin: Maryland, United States; Orsay, France; Chiba, Japan; Edinburgh, Scotland

Institutions: National Institutes of Health, Campus University Paris-Saclay, Kazusa DNA Research Institute, University of Edinburgh

Quote: “Telomerase/telomere-targeting therapy is a potentially promising approach for cancer treatment because even transient telomere dysfunction can induce chromosomal instability (CIN) and may be a barrier to tumor growth. We recently developed a dual-HAC (Human Artificial Chromosome) assay that enables identification and ranking of compounds that induce CIN as a result of telomere dysfunction.”


RESEARCH PAPER: RNA EXPRESSION DIFFERENCES IN PROSTATE TUMORS AND TUMOR-ADJACENT STROMA BETWEEN BLACK AND WHITE AMERICANS

Origin: California, South Carolina, United States

Institution:s University of California, Medical University of South Carolina

Quote: “Prostate cancer (PCa) in Black Americans (BA) is diagnosed at an earlier median age and a more advanced stage than PCa in White Americans (WA). Tumor-adjacent stroma (TAS) plays a critical role in tumorigenesis of prostate cancer.”


RESEARCH PAPER: NEXT-GENERATION MULTIMODALITY OF NUTRIGENOMIC CANCER THERAPY: SULFORAPHANE IN COMBINATION WITH ACETAZOLAMIDE ACTIVELY TARGET BRONCHIAL CARCINOID CANCER IN DISABLING THE PI3K/AKT/MTOR SURVIVAL PATHWAY AND INDUCING APOPTOSIS

Origin: Ontario, Toronto, Canada; Massachusetts, Illinois, Delaware, United States; San Giovanni Rotondo, Italy; Assam, India

Institutions: The Hospital for Sick Children, Queen’s University, IRCCS Casa Sollievo della Sofferenza, University of Chicago, Q.P.S. Holdings LLC, University of Toronto, Indian Institute of Technology, Forsyth Institute

Quote: “In this study, we investigated the mechanism(s) by which SFN [sulforaphane] combined with AZ [acetazolamide] exerts its nutrigenetic therapeutic effect on BC [breast cancer] cell lines and in BC xenograft tissues derived from H727 and H720 BC cells previously developed in NOD/SCID mice.”


RESEARCH PAPER: THE IMPACT OF NEOADJUVANT CONCURRENT CHEMORADIATION ON EXOSOMAL MARKERS (CD63 AND CD9) EXPRESSION AND THEIR PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH RECTAL ADENOCARCINOMA

Origin: Alabama, Minnesota, Ohio, Texas, Massachusetts, United States

Institutions: The University of Alabama at Birmingham, Mayo Clinic, Case Western Reserve University, The University of South Alabama, Texas Tech University Health Sciences Center, Harvard T.H. Chan School of Public Health

Quote: “Exosomes have pivotal roles in cancer development. The impact of neoadjuvant concurrent chemoradiation (NCCR) on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma are yet to be explored.”


RESEARCH PAPER: IDENTIFICATION OF MIR-203A, MIR-10A, AND MIR-194 AS PREDICTORS FOR RISK OF LYMPHOVASCULAR INVASION IN HEAD AND NECK CANCERS

Origin: Texas, United States

Institutions: Texas A&M University, Texas A&M Health Science Center

Quote: “Lymphovascular invasion (LVI) is an important prognostic indicator of lymph node metastasis and disease aggressiveness but clear molecular mechanisms mediating this in head and neck cancers (HNSC) remain undefined. To identify important microRNAs (miRNAs) in HNSC that associate with and are also predictive of increased risk of LVI, we used a combination of clustering algorithms, multiple regression analyses and machine learning approaches and analyzed miRNA expression profiles in the TCGA HNSC database.”


RESEARCH PAPER: JUND ACCENTUATES ARECOLINE-INDUCED DISRUPTION OF TIGHT JUNCTIONS AND PROMOTES EPITHELIAL-TO-MESENCHYMAL TRANSITION BY ASSOCIATION WITH NEAT1 LNCRNA

Origin: West Bengal, Assam, India

Institutions: University of Calcutta, Silchar Medical College, Assam University, Saha Institute of Nuclear Physics

Quote: “Head and neck cancers are highly prevalent in south-east Asia, primarily due to betel nut chewing. Arecoline, the primary alkaloid is highly carcinogenic; however its role in promoting tumorigenesis by disrupting junctional complexes and increasing risk of metastasis is not well delineated.”


RESEARCH PAPER: ACTIONABILITY EVALUATION OF BILIARY TRACT CANCER BY GENOME TRANSCRIPTOME ANALYSIS AND ASIAN CANCER KNOWLEDGEBASE

Origin: Yokohama, Sapporo, Japan; Seoul, Republic of Korea

Institutions: RIKEN Center for Integrative Medical Sciences, Hokkaido University Faculty of Medicine, Geninus Inc., Samsung Medical Center

Quote: “Treatment options for biliary tract cancer (BTC) are very limited. It is necessary to investigate actionable genes and candidate drugs using a sophisticated knowledgebase (KB) and characterize BTCs immunologically for evaluating the actionability of molecular and immune therapies.”


REVIEW: MULTIDISCIPLINARY CLINICS IN PROSTATE CANCER

Origin: Texas, United States

Institution: The University of Texas MD Anderson Cancer Center

Quote: “Here, we reflect on challenges and opportunities associated with MDCs [multidisciplinary clinics] for the treatment of prostate cancer.”


RESEARCH PERSPECTIVE: DEVELOPING NEXT GENERATION IMMUNOMODULATORY DRUGS AND THEIR COMBINATIONS IN MULTIPLE MYELOMA

Origin: New Jersey, United States

Institution: Bristol Myers Squibb

Quote: “Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs®) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents. Currently, more potent next generation cereblon E3 ligase modulators (CELMoDs®) – iberdomide (IBER) and CC-92480 are in clinical development.”


Click here to read Oncotarget’s Volume 12, Issue #15.

YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube

Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read—without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.

For media inquiries, please contact media@impactjournals.com.

Leave a Reply

Your email address will not be published.